5-Year Return on Invested Incremental Capital (5-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 5-year.
Cosciens Biopharma's 5-Year ROIIC % for the quarter that ended in Dec. 2025 was 301.58%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Cosciens Biopharma's 5-Year ROIIC % or its related term are showing as below:
CSCIF's 5-Year ROIIC % is ranked better than 90.92% of 1178
companies
in the Biotechnology industry
Industry Median: -11.255
vs CSCIF: 301.58
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Cosciens Biopharma 5-Year ROIIC % Related Terms
Cosciens Biopharma 5-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Cosciens Biopharma's 5-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CSCIF vs VRTX, REGN, ALNY: 5-Year ROIIC % Comparison
For the Biotechnology subindustry, Cosciens Biopharma's 5-Year ROIIC %, along with its competitors' market caps and 5-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cosciens Biopharma 5-Year ROIIC % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cosciens Biopharma's 5-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Cosciens Biopharma's 5-Year ROIIC % falls into.
Cosciens Biopharma's 5-Year ROIIC % for the quarter that ended in Dec. 2025 is calculated as:
5-Year ROIIC %
=
5-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
5-Year Incremental Invested Capital**
=
( -10.365 (Dec. 2025) - 1.84 (Dec. 2020) )
/
( 12.59 (Dec. 2025) - 17.871 (Dec. 2020) )
=
-12.205
/
-5.281
=
231.11%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 5-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Cosciens Biopharma (CSCIF) has a 5-Year ROIIC % of 301.58 as of Dec. 2025. 5-Year ROIIC % measures the change in earnings as a percentage of change in investment over 5-year. View historical data on Cosciens Biopharma and its competitors. According to the industry distribution chart, Cosciens Biopharma ranks #107 out of 1178 companies in the Biotechnology industry, placing it in the top 9.1%.
Is Cosciens Biopharma's 5-Year ROIIC % too high?
Cosciens Biopharma's current 5-Year ROIIC % is 301.58. Based on the distribution chart, Cosciens Biopharma ranks #107 out of 1178 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Cosciens Biopharma has a GF Score™ of 62/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Cosciens Biopharma's 5-Year ROIIC % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Cosciens Biopharma ranks #107 out of 1178 companies for 5-Year ROIIC %. This places Cosciens Biopharma in the top 9% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year ROIIC % for a Biotechnology company?
A good 5-Year ROIIC % depends on the Biotechnology industry context. However, 5-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year ROIIC % mean?
A high 5-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 5-Year ROIIC % measures the change in earnings as a percentage of change in investment over 5-year. View historical data on Cosciens Biopharma and its competitors. Cosciens Biopharma's current 5-Year ROIIC % is 301.58. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cosciens Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Cosciens Biopharma (CSCIF) is currently considered Fairly Valued. The stock's GF Value™ is $2.38, compared to a current price of $2.29 — trading 3.8% below its estimated fair value. The current 5-Year ROIIC % is 301.58. Cosciens Biopharma's overall GF Score™ is 62/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year ROIIC % calculated?
5-Year ROIIC % is calculated from a company's financial statements. For Cosciens Biopharma (CSCIF), the current 5-Year ROIIC % is 301.58 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cosciens Biopharma (CSCIF) Overvalued in 2026?
Based on GuruFocus' analysis, Cosciens Biopharma stock appears to be undervalued.
The current stock price of $2.29 is trading 3.8% below its estimated GF Value™ of $2.38.
GuruFocus considers Cosciens Biopharma to be Fairly Valued.
Key valuation signals for CSCIF:
5-Year ROIIC %: 301.58
GF Value™: $2.38 vs. price of $2.29 (3.8% below fair value)
No single metric tells the full story. See the CSCIF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cosciens Biopharma Inc is a biopharmaceutical company developing and commercializing pharmaceutical and diagnostic products and active ingredients for the healthcare and cosmetics industries. It operates through two segments: Active Ingredient and Biopharmaceutical. The Active Ingredient segment, which generates maximum revenue, focuses on plant-based ingredients derived from oats and other renewable resources, including oat beta glucan, oat oil, and avenanthramides. The Biopharmaceutical segment focuses on the development and commercialization of therapeutics and diagnostic tests, including its product Macrilen, and advancing a pre-clinical pipeline targeting unmet medical needs, particularly in rare or orphan indications. It operates in Canada, Germany, the United States, and Austria.
62GF Score
Get the complete analysis for CSCIF
5-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSCIF has been successfully added to your 
